1012879-55-8

Basic information

• Product Name: 1-(diphenylmethylene)-2-(quinolin-6-yl)hydrazine
• Synonyms: 1-(diphenylmethylene)-2-(quinolin-6-yl)hydrazine
• CAS NO: 1012879-55-8
• Molecular Weight: 323.397
• Mol File: 1012879-55-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(diphenylmethylene)-2-(quinolin-6-yl)hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(diphenylmethylene)-2-(quinolin-6-yl)hydrazine(1012879-55-8)
• EPA Substance Registry System: 1-(diphenylmethylene)-2-(quinolin-6-yl)hydrazine(1012879-55-8)

Safety Data

• Hazardous Substances Data: 1012879-55-8(Hazardous Substances Data)

Upstream product

• 5350-57-2 benzophenone hydrazone 
• 173089-80-0 quinolin-6-yl triflate 
• 119-61-9 benzophenone 
• 16023-69-1 6-quinolinylhydrazine 
• 580-16-5 6-hydroxyquinoline 

Downstream Products

• 1020172-07-9 DCC-2036 
• 1020172-28-4 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-5-(2-(methylamino)pyrimidin-4-yloxy)phenyl)urea 
• 897373-62-5 5-tert-butyl-2-quinolin-6-yl-2H-pyrazol-3-ylamine 

Relevant articles and documents

Imaging of Tie2 with a Fluorescently Labeled Small Molecule Affinity Ligand

The receptor tyrosine kinase inhibitor, Tie2, has significant roles in endothelial signaling and angiogenesis and is relevant in the pathophysiology of several diseases. However, there are relatively few small molecule probes available to study Tie2, maki

METHODS OF USING REBASTINIB IN THE TREATMENT OF DISORDERS

Described herein are methods of treating various disorders in patients in need thereof, comprising administering to the patient the compound of Formula (I) or a pharmaceutically acceptable salt thereof. Exemplary disorders that can be treated by the methods described herein include gynecologic carcinosarcomas, endometrial adenocarcinomas, mesotheliomas, ovarian cancers, pancreatic ductal adenocarcinomas, and lung cancers.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.